Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin. - Wikidata - wikimedia - TriplyDB

Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

http://www.wikidata.org/entity/Q37296274

about

Metabolic interrogation as a tool to optimize chemotherapeutic regimens.Oxaliplatin for the treatment of ovarian cancer.Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database.

P2860

Q33566853-3C2B267D-B956-49B8-9914-7A0453C94733 Q38540596-D01D0665-5F08-4357-9377-24FAC9DBFCC3 Q47727860-BA824F6D-9E03-4BA3-A184-60530C8FC12E

P2860

Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

http://www.wikidata.org/entity/Q37296274

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@en

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@nl

type

label

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@en

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@nl

prefLabel

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@en

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@nl

P1433

Q37296274-1A093A1B-FC03-49A4-BAC6-59A90DEA3A92

P1476

Q37296274-1FEFB621-78D3-4ED3-AF18-B23F350C81A1

P2093

Q37296274-05C1C036-1C89-4181-A9A3-0A0ABAD42479

Q37296274-1947BB84-0114-4195-A3B9-F99642F5A070

Q37296274-337A6976-43EC-414E-80E1-8C97EC3C46BD

Q37296274-5FFCE153-3390-4EC9-9406-6DC2531E2D93

Q37296274-663654BA-A577-41FB-B363-2A1716ED3A09

Q37296274-96E75AA9-751B-4034-8DE3-764C7E0EEF74

Q37296274-C80CE087-7E46-4925-83B2-B151BD452CFC

P2860

Q37296274-270FF70F-1473-441D-A682-D527C8DEDC00

Q37296274-30495B40-E29E-4E3F-9827-4F70C47579F3

Q37296274-40B3315E-F49D-4B11-B934-C7FFC9A8EFBA

Q37296274-4205A7A8-CDF6-4B53-884C-5C86EDC58E5C

Q37296274-46787F89-2965-4E22-88EB-A9BD73618403

Q37296274-48817E6A-E19C-4EF2-88E3-A293EC4FBED1

Q37296274-48A6F014-AC50-4FED-9212-EF19ED47D096

Q37296274-4917EAFE-9307-41C3-BE35-CAE36E390742

Q37296274-4E99E9C3-8E40-4D59-B18F-5AC494DAE3F3

Q37296274-57A00F3E-721F-49A2-8CEC-C25B46760933

P304

Q37296274-8ED53D4D-E721-4C96-B41B-4262CC7F8CED

P31

Q37296274-2090E615-F255-48FD-A924-5EF228D06CD4

P356

Q37296274-A04C6C70-E3EE-427D-AF30-0DF3AB3295CB

P433

Q37296274-9393EF4C-744D-475D-900E-BCBECAC6A2BD

P478

Q37296274-35D40613-0FC9-416E-9F28-F2C3BEAD0BC6

P577

Q37296274-59B7D0E2-BF7D-49C9-A55C-D4DE5F151AFC

P698

Q37296274-CB7137AB-7A2C-41E4-86A2-1167B1496FD3

P932

Q37296274-0EF794BA-AA23-40AE-ADF2-9CE902595D72

P356

IGC.0000000000000307

P1433

International Journal of Gynecological Cancer

P1476

Oxaliplatin is a safe alternat ...... ivity reaction to Carboplatin.

@en

P2093

Austin Miller

http://www.w3.org/2001/XMLSchema#string

Bonnie L Blum

http://www.w3.org/2001/XMLSchema#string

Grazyna C Riebandt

http://www.w3.org/2001/XMLSchema#string

Kunle O Odunsi

http://www.w3.org/2001/XMLSchema#string

Nonna V Kolomeyevskaya

http://www.w3.org/2001/XMLSchema#string

Peter J Frederick

http://www.w3.org/2001/XMLSchema#string

Shashikant B Lele

http://www.w3.org/2001/XMLSchema#string

P2860

Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.

Paclitaxel plus carboplatin in the treatment of ovarian cancer.

A phase 3 trial of bevacizumab in ovarian cancer.

Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.

Carboplatin hypersensitivity.

Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.

P304

42-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IGC.0000000000000307

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25356535

http://www.w3.org/2001/XMLSchema#string

P932

5042199

http://www.w3.org/2001/XMLSchema#string